^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CUL1-BRAF fusion

    i
    Other names: BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1, CUL1, Cullin 1, Cullin-1, CUL-1
    Entrez ID:
    673; 8454
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    1year
    BRAF Fusion Driven Papillary Thyroid Carcinoma (PTC): A Genomic Landscape Study (USCAP 2023)
    BRAF fus driven clinically advanced PTC is a rare (2.2%) form of thyroid cancer which appears to have more in common with BRAF V600E driven PTC than BRAF WT PTC. Further study of these uncommon tumors and comparing their responses to RAF and MEK inhibitors in a clinical trial setting appears warranted.
    Tumor mutational burden • PD(L)-1 Biomarker • MSi-H Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • AGK (Acylglycerol Kinase) • CUL1 (Cullin 1) • FUS (FUS RNA Binding Protein) • MEN1 (Menin 1)
    |
    PD-L1 expression • BRAF V600E • MSI-H/dMMR • BRAF V600 • BRAF wild-type • TMB-L • BRAF fusion • CUL1-BRAF fusion
    |
    PD-L1 IHC 22C3 pharmDx
    over1year
    BRAF Fusion Driven Papillary Thyroid Carcinoma (PTC): A Genomic Landscape Study (USCAP 2023)
    BRAF fus driven clinically advanced PTC is a rare (2.2%) form of thyroid cancer which appears to have more in common with BRAF V600E driven PTC than BRAF WT PTC. Further study of these uncommon tumors and comparing their responses to RAF and MEK inhibitors in a clinical trial setting appears warranted.
    Tumor mutational burden • PD(L)-1 Biomarker • MSi-H Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • AGK (Acylglycerol Kinase) • CUL1 (Cullin 1) • FUS (FUS RNA Binding Protein) • MEN1 (Menin 1)
    |
    PD-L1 expression • BRAF V600E • MSI-H/dMMR • BRAF V600 • BRAF wild-type • TMB-L • BRAF fusion • CUL1-BRAF fusion
    |
    PD-L1 IHC 22C3 pharmDx